Novus Pharma Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2004)

Organization Overview

First Clinical Trial
2009
NCT00959959
First Marketed Drug
2023
vancomycin (Vancocin)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Anelixis Therapeutics, Inc. | Anelixis Therapeutics, LLC | Novus Therapeutics, Inc | Tokai Pharmaceuticals | Tokai Pharmaceuticals, Inc. | ZHEJIANG NOVUS PHARM